# Resource Summary Report

Generated by NIF on Sep 5, 2026

## Miltenyi Mouse Tumor Dissociation Kit

RRID:SCR_020285
Type: Tool

### Proper Citation

Miltenyi Mouse Tumor Dissociation Kit (RRID:SCR_020285)

### Resource Information

**URL:** https://www.miltenyibiotec.com/US-en/products/tumor-dissociation-kit-mouse.html#130-096-730

**Proper Citation:** Miltenyi Mouse Tumor Dissociation Kit (RRID:SCR_020285)

**Description:** Developed for generation of single cell suspensions from tumor tissue generated by implanting mouse tumor material into second mouse. Kit is optimized for high yield of tumor cells and tumor infiltrating lymphocytes.

**Resource Type:** instrument resource

**Keywords:** Miltenyi, Dissociation Kit, Instrument, Equipment, USEDit,

**Availability:** Commercially available

**Specification URL:** https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_020285.pdf

**Resource Name:** Miltenyi Mouse Tumor Dissociation Kit

**Resource ID:** SCR_020285

**Alternate IDs:** Model_Number_Mouse_Tumor

**Record Creation Time:** 20220129T080349+0000

**Record Last Update:** 20260903T235626+0000

### Ratings and Alerts

No rating or validation information has been found for Miltenyi Mouse Tumor Dissociation Kit.

No alerts have been found for Miltenyi Mouse Tumor Dissociation Kit.

## Data and Source Information

**Source:** SciCrunch Registry

## Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at NIF .


Martín A, et al. (2026) Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research.

Xu X, et al. (2026) A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer research, 86(15), 3666.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science advances, 11(29), eadw5228.

Liu Y, et al. (2025) Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer discovery, 15(1), 162.

Ren Y, et al. (2025) eEF2K promotes immune evasion in melanoma via Cyclin D1-mediated stabilization of PD-L1. Journal of immunology (Baltimore, Md. : 1950).

Wang S, et al. (2023) Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with ?PDL1 in ovarian cancer. Cell death & disease, 14(11), 775.

Yang Z, et al. (2022) Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer discovery, 12(8), 1942.

Stern LA, et al. (2022) Engineered IL13 variants direct specificity of IL13R?2-targeted CAR T cell therapy. Proceedings of the National Academy of Sciences of the United States of America, 119(33), e2112006119.

Wu MJ, et al. (2022) Mutant IDH Inhibits IFN?-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer discovery, 12(3), 812.

Anadon CM, et al. (2022) Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer cell, 40(5), 545.

Obradovic A, et al. (2021) Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell, 184(11), 2988.

Ramos MIP, et al. (2021) Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. eLife, 10.